NPS Pharmaceuticals

NPS Pharmaceuticals is engaged in the discovery and development, and is preparing for the commercialization of therapeutic small molecules and recombinant proteins. Current product candidates include treatments for bone and mineral disorders (osteoporosis & hyperparathyroidism), gastrointestinal disorders (GI) and central nervous system disorders (CNS).

Activity:

- Clinical Trials
- Licensing & Business Development
- Market Research & Marketing
- Regulatory Affairs & Legal Services
- Research & Development

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Alzheimer's Disease
- Central nervous system
- Gastrointestinal
- Mental Health
- Neurology
- Obesity
- Pain
- Stroke

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe , Asia

c. Countries active: United States of America

Corporate data:

Number of Employees: 183

Turnover:

Amount:	Year:	Currency:
2200000	2002	US Dollar

Year founded: 1986

Stock options:

	Symbol	Exchange
1	NPSP	Nasdaq

Partners / Alliances: Partners include: Amgen, Kirin, GlaxoSmithKline, Janssen, and AstraZeneca.